Changes in Lipid Concentrations in Patients with Type 2 Diabetes on Once-Weekly Dulaglutide 1.5 mg: Post-hoc Pooled Analysis of the AWARD Trials

被引：0
|
作者：
Sattar, Naveed A.
Garcia-Perez, Luis E.
Tao, Yebin
Thieu, Vivian T.
Pavo, Imre
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1090-P
引用
收藏
页码：A288 / A289
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of once-weekly dulaglutide monotherapy compared to glimepiride in Chinese patients with type 2 diabetes mellitus
    Wang, Weiqing
    Li, Pengfei
    Yang, Jun
    Gu, Liqun
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 : 10 - 11
  • [42] Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Yan Zhou
    Jiankun Zhu
    Haiya Wu
    Yuying Deng
    Qiuhe Ji
    [J]. Diabetes Therapy, 2021, 12 : 2677 - 2690
  • [43] Efficacy of dulaglutide 1.5 mg combined with insulin in older, poorly controlled insulin-treated patients with long-standing type 2 diabetes: a post-hoc analysis
    Lando, L. Fernandez
    Patel, H.
    Yu, M.
    Pantalone, K. M.
    [J]. DIABETOLOGIA, 2017, 60 : S382 - S383
  • [44] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Vidal, Josep
    Malkin, Samuel J. P.
    Hunt, Barnaby
    Martin, Virginia
    Hallen, Nino
    Javier Ortega, Francisco
    [J]. DIABETES THERAPY, 2020, 11 (02) : 509 - 521
  • [45] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Josep Vidal
    Samuel J. P. Malkin
    Barnaby Hunt
    Virginia Martín
    Nino Hallén
    Francisco Javier Ortega
    [J]. Diabetes Therapy, 2020, 11 : 509 - 521
  • [46] COST-EFFECTIVENESS OF DULAGLUTIDE 1.5MG ONCE WEEKLY FOR THE TREATMENT OF PATIENTS WITH TYPE TWO DIABETES MELLITUS IN SWEDEN
    Raibouaa, A.
    Borgeke, H.
    Alexiou, D.
    Lowin, J.
    Norrbacka, K.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A607 - A607
  • [47] Efficacy of Dulaglutide 1.5 mg Combined with Insulin in Older, Poorly Controlled Insulin-Treated Patients with Long-Standing Type 2 Diabetes: A Post-hoc Analysis of AWARD-4 and-9
    Pantalone, Kevin
    Patel, Hiren
    Yu, Maria
    Lando, Laura Fernandez
    [J]. DIABETES, 2017, 66 : A288 - A288
  • [48] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Qifu Li
    Qiqi Zhang
    Rui Wang
    Tianpei Hong
    [J]. Diabetes Therapy, 2022, 13 : 161 - 173
  • [49] CONTINUOUS GLUCOSE MONITORING IN INSULINEXPERIENCED INDIVIDUALS WITH TYPE 2 DIABETES SWITCHED TO ONCE-WEEKLY INSULIN ICODEC VERSUS ONCE-DAILY COMPARATORS IN ONWARDS 2 AND 4: POST-HOC ANALYSIS
    Bajaj, H.
    Asbjornsdottir, B.
    Lehrskov, L. L.
    Mathieu, C.
    Philis-Tsimikas, A.
    Wang, N.
    Battelino, T.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A52 - A53
  • [50] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Li, Qifu
    Zhang, Qiqi
    Wang, Rui
    Hong, Tianpei
    [J]. DIABETES THERAPY, 2022, 13 (01) : 161 - 173
12345